Skip to main content Accessibility help
×
Home

Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis

  • S. A. Hiles (a1), A. L. Baker (a1), T. de Malmanche (a2) and J. Attia (a3) (a4)

Abstract

Background

Cross-sectional studies support an association between depression and inflammatory markers. However, little is known of their relationship in the context of antidepressant treatment. Our aim was to explore via meta-analysis whether antidepressant treatment is associated with a reduction in three inflammatory markers associated with depression.

Method

A computerized search of EMBASE, Medline, PsycINFO and Cochrane Library databases was completed using subject headings for depression and either interleukin-6, C-reactive protein or interleukin-10, selecting studies which reported circulating levels of inflammatory markers before and after antidepressant treatment for people with depression. Outcome and moderator variables were coded for analysis, including inflammatory marker change, depression severity change, age, gender ratio, assay brand, treatment response and weight change.

Results

Pooled effect sizes showed a significant decrease in interleukin-6 (n=14, d=−0.42, p=0.02), marginally significant decrease in C-reactive protein (n=8, d=−0.57, p=0.05) and a non-significant decrease in interleukin-10 (n=3, d=−0.45, p=0.14) after treatment. High levels of heterogeneity were observed, which may be associated with clinical variations between the studies such as weight gain, anxiety, incomplete remission and other individual differences and co-morbidities.

Conclusions

The findings of this meta-analysis indicate that there may be a normalization of overactive inflammatory processes following antidepressant treatment.

Copyright

Corresponding author

*Address for correspondence: Ms. S. A. Hiles, Centre for Brain and Mental Health Research, University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia. (Email: sarah.hiles@uon.edu.au)

References

Hide All
Basterzi, AD, Aydemir, C, Kisa, C, Aksaray, S, Tuzer, V, Yazici, K, Goka, E (2005). IL-6 levels decrease with SSRI treatment in patients with major depression. Human Psychopharmacology 20, 473476.
Bland, JM, Altman, DG (1994). Statistics notes: some examples of regression towards the mean. British Medical Journal 309, 780.
Borenstein, M, Hedges, LV, Higgins, JPT, Rothstein, HR (2009). Introduction to Meta-analysis. John Wiley & Sons: Chichester, UK.
Bossola, M, Ciciarelli, C, Di Stasio, E, Conte, GL, Vulpio, C, Luciani, G, Tazza, L (2010). Correlates of symptoms of depression and anxiety in chronic hemodialysis patients. General Hospital Psychiatry 32, 125131.
Carvalho, LA, Garner, BA, Dew, T, Fazakerley, H, Pariante, CM (2010). Antidepressants, but not antipsychotics, modulate GR function in human whole blood: an insight into molecular mechanisms. European Neuropsychopharmacology 20, 379387.
Carvalho, LA, Pariante, CM (2008). In vitro modulation of the glucocorticoid receptor by antidepressants. Stress: The International Journal on the Biology of Stress 11, 411424.
Chen, Y-C, Lin, W-W, Chen, Y-J, Mao, W-C, Hung, Y-J (2010). Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediators of Inflammation. Published online: 18 May 2010. doi:10.1155/2010/573594.
Dawood, T, Lambert, EA, Barton, DA, Laude, D, Elghozi, JL, Esler, MD, Haikerwal, D, Kaye, DM, Hotchkin, EJ, Lambert, GW (2007). Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertension Research 30, 285293.
Dowlati, Y, Herrmann, N, Swardfager, W, Liu, H, Sham, L, Reim, EK, Lanctôt, KL (2010). A meta-analysis of cytokines in major depression. Biological Psychiatry 67, 446457.
Egger, M, Davey Smith, G, Schneider, M, Minder, C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629634.
Evans, DL, Charney, DS, Lewis, L, Golden, RN, Gorman, JM, Krishnan, KRR, Nemeroff, CB, Bremner, JD, Carney, RM, Coyne, JC, Delong, MR, Frasure-Smith, N, Glassman, AH, Gold, PW, Grant, I, Gwyther, L, Ironson, G, Johnson, RL, Kanner, AM, Katon, WJ, Kaufmann, PG, Keefe, FJ, Ketter, T, Laughren, TP, Leserman, J, Lyketsos, CG, McDonald, WM, McEwen, BS, Miller, AH, Musselman, D, O'Connor, C, Petitto, JM, Pollock, BG, Robinson, RG, Roose, SP, Rowland, J, Sheline, Y, Sheps, DS, Simon, G, Spiegel, D, Stunkard, A, Sunderland, T, Tibbits, JP, Valvo, WJ (2005). Mood disorders in the medically ill: scientific review and recommendations. Biological Psychiatry 58, 175189.
Fornaro, M, Martino, M, Battaglia, F, Colicchio, S, Perugi, G (2011). Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation. Neuropsychiatric Disease and Treatment 7, 5156.
Gabay, C, Kushner, I (1999). Acute-phase proteins and other systemic responses to inflammation. New England Journal of Medicine 340, 448454.
Hernandez, ME, Mendieta, D, Martinez-Fong, D, Loria, F, Moreno, J, Estrada, I, Bojalil, R, Pavon, L (2008). Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. European Neuropsychopharmacology 18, 917924.
Higgins, JPT, Thompson, SG, Deeks, JJ, Altman, DG (2003). Measuring inconsistency in meta-analyses. British Medical Journal 327, 557560.
Howren, MB, Lamkin, DM, Suls, J (2009). Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 71, 171186.
Irwin, MR, Miller, AH (2007). Depressive disorders and immunity: 20 years of progress and discovery. Brain, Behavior, and Immunity 21, 374383.
Janssen, DGA, Caniato, RN, Verster, JC, Baune, BT (2010). A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Human Psychopharmacology 25, 201215.
Jazayeri, S, Keshavarz, SA, Tehrani-Doost, M, Djalali, M, Hosseini, M, Amini, H, Chamari, M, Djazayery, A (2010). Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Research 178, 112115.
Kagaya, A, Kugaya, A, Takebayashi, M, Fukue-Saeki, M, Saeki, T, Yamawaki, S, Uchitomi, Y (2001). Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 43, 5962.
Kenis, G, Maes, M (2002). Effects of antidepressants on the production of cytokines. International Journal of Neuropsychopharmacology 5, 401–142.
Khan, AMD, Brodhead, AEMS, Schwartz, KAMS, Kolts, RLP, Brown, WAMD (2005). Sex differences in antidepressant response in recent antidepressant clinical trials. Journal of Clinical Psychopharmacology 25, 318324.
Kubera, M, Kenis, G, Bosmans, E, Zieba, A, Dudek, D, Nowak, G, Maes, M (2000). Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Polish Journal of Pharmacology 52, 237241.
Lanquillon, S, Krieg, JC, Bening-Abu-Shach, U, Vedder, H (2000). Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370379.
Leo, R, Di Lorenzo, G, Tesauro, M, Razzini, C, Forleo, GB, Chiricolo, G, Cola, C, Zanasi, M, Troisi, A, Siracusano, A, Lauro, R, Romeo, F (2006). Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. Journal of Clinical Psychiatry 67, 17601766.
Lindqvist, D, Janelidze, S, Hagell, P, Erhardt, S, Samuelsson, M, Minthon, L, Hansson, O, Bjorkqvist, M, Traskman-Bendz, L, Brundin, L (2009). Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biological Psychiatry 66, 287292.
Mackay, GM, Forrest, CM, Christofides, J, Bridel, MA, Mitchell, S, Cowlard, R, Stone, TW, Darlington, LG (2009). Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clinical and Experimental Pharmacology and Physiology 36, 425435.
Maes, M (2001). The immunoregulatory effects of antidepressants. Human Psychopharmacology: Clinical and Experimental 16, 95103.
Maes, M, Bosmans, E, De Jongh, R, Kenis, G, Vandoolaeghe, E, Neels, H (1997). Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9, 853858.
Maes, M, Meltzer, HY, Bosmans, E, Bergmans, R, Vandoolaeghe, E, Ranjan, R, Desnyder, R (1995). Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of Affective Disorders 34, 301309.
Maes, M, Yirmyia, R, Noraberg, J, Brene, S, Hibbeln, J, Perini, G, Kubera, M, Bob, P, Lerer, B, Maj, M (2009). The inflammatory and neurodegenerative hypothesis of depression: leads for future research and new drug developments in depression. Metabolic Brain Disease 24, 2753.
Mikova, O, Yakimova, R, Bosmans, E, Kenis, G, Maes, M (2001). Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. European Neuropsychopharmacology 11, 203208.
Miller, AH, Maletic, V, Raison, CL (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 65, 732741.
Moore, KW, de Waal Malefyt, R, Coffman, RL, O'Garra, A (2001). Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology 19, 683765.
O'Brien, SM, Scott, LV, Dinan, TG (2006). Antidepressant therapy and C-reactive protein levels. British Journal of Psychiatry 188, 449452.
O'Donovan, A, Hughes, BM, Slavich, GM, Lynch, L, Cronin, M-T, O'Farrelly, C, Malone, KM (2010). Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain, Behavior, and Immunity 24, 10741077.
Park, HS, Park, JY, Yu, R (2005). Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Research and Clinical Practice 69, 2935.
Pizzi, C, Mancini, S, Angeloni, L, Fontana, F, Manzoli, L, Costa, GM (2009). Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology & Therapeutics 86, 527–32.
Pudar Hozo, S, Djulbegovic, B, Hozo, I (2005). Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 5(13).
Rosenthal, R (1979). The file drawer problem and tolerance for null results. Psychological Bulletin 86, 638641.
Rothermundt, M, Arolt, V, Fenker, J, Gutbrodt, H, Peters, M, Kirchner, H (2001). Different immune patterns in melancholic and non-melancholic major depression. European Archives of Psychiatry and Clinical Neuroscience 251, 9097.
Rush, AJ, Zimmerman, M, Wisniewski, SR, Fava, M, Hollon, SD, Warden, D, Biggs, MM, Shores-Wilson, K, Shelton, RC, Luther, JF, Thomas, B, Trivedi, MH (2005). Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. Journal of Affective Disorders 87, 4355.
Serretti, A, Mandelli, L (2010). Antidepressants and body weight: a comprehensive review and meta-analysis. Journal of Clinical Psychiatry 71, 12591272.
Sluzewska, A, Rybakowski, JK, Laciak, M, Mackiewicz, A, Sobieska, M, Wiktorowicz, K (1995). Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Annals of the New York Academy of Sciences 762, 474476.
Sluzewska, A, Sobieska, M, Rybakowski, JK (1997). Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 35, 123127.
Song, C, Halbreich, U, Han, C, Leonard, BE, Luo, H (2009). Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 42, 182188.
Tuglu, C, Kara, SH, Caliyurt, O, Vardar, E, Abay, E (2003). Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 170, 429433.
Tummers, B, van der Laan, J, Huyser, K (2008). Data Thief III, v. 1.5, computer software (http://datathief.org/). Accessed 8 September 2010.
Yao, H, Tao, L-G, Zhang, X-B, Sha, W-W, Hou, G, Zhang, Z-J (2004). Variety of cell-mediated immunity and the metabolic products of monoamine neural transmitter in depression patients before and after therapy. Chinese Journal of Clinical Rehabilitation 8, 29782979.
Yoshimura, R, Hori, H, Ikenouchi-Sugita, A, Umene-Nakano, W, Ueda, N, Nakamura, J (2009). Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33, 722726.
Zorrilla, EP, Luborsky, L, McKay, JR, Rosenthal, R, Houldin, A, Tax, A, McCorkle, R, Seligman, DA, Schmidt, K (2001). The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain, Behavior and Immunity 15, 199226.

Keywords

Type Description Title
WORD
Supplementary materials

Hiles Supplementary Material
Table S1.doc

 Word (126 KB)
126 KB

Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis

  • S. A. Hiles (a1), A. L. Baker (a1), T. de Malmanche (a2) and J. Attia (a3) (a4)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed